Clinical Trial Update: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study evaluating the combination of ruxolitinib and CPX-351 in advanced phase myeloproliferative neoplasms was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Essential Thrombocythemia
• Myelofibrosis
• Myeloproliferative Neoplasms
• Polycythemia Vera

Drugs mentioned

• Jakafi (ruxolitinib)
• Vyxeos (CPX-351)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Essential Thrombocythemia, Myelofibrosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-04-24